Simply Wall St
3 min read
-
Recently, Canaccord Genuity and CCORF initiated coverage on Pulse Biosciences, highlighting its nanosecond pulsed field ablation platform for cardiac applications and pointing to recent insider share purchases by top executives.
-
The combination of external analyst attention and meaningful insider buying has drawn fresh focus to Pulse Biosciences’ differentiated technology in the competitive cardiac ablation field.
-
Next, we’ll examine how this new bullish analyst coverage around Pulse’s nanosecond pulsed field ablation platform could reshape its investment narrative.
This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
Pulse Biosciences Investment Narrative Recap
To own Pulse Biosciences, you have to believe its nanosecond pulsed field ablation can carve out a meaningful role in thyroid and cardiac procedures despite early stage revenues and sizable losses. The latest bullish initiations spotlight the cardiac catheter platform and insider buying, but they do not change the near term reality that pivotal AF data and trial progress are the key catalyst, while high cash burn and potential future dilution remain the biggest risk.
Among recent announcements, the expanded first in human data for the nPulse Cardiac Catheter System at Heart Rhythm 2026 looks most relevant. Strong procedural success and safety in 177 patients provide important clinical context for Canaccord and CCORF’s focus on the AF opportunity, and help frame how upcoming NANOPULSE AF pivotal milestones could either support or challenge the more optimistic elements of the new coverage.
Yet against this optimism, the possibility of persistent high operating losses and additional capital needs is something investors should be aware of…
Read the full narrative on Pulse Biosciences (it’s free!)
Pulse Biosciences’ narrative projects $29.7 million revenue and $3.9 million earnings by 2028. This requires 601.5% yearly revenue growth and an earnings increase of about $78.6 million from -$74.7 million today.
Uncover how Pulse Biosciences’ forecasts yield a $22.00 fair value, a 11% downside to its current price.
Exploring Other Perspectives
Before this week’s coverage, the most bullish analysts were assuming revenue could climb toward about US$42.3 million by 2029 with earnings of roughly US$5.7 million, which is far more optimistic than consensus and sits alongside the risk that cash burn of around US$19.4 million a quarter may eventually force fresh funding, so it is worth comparing how your own expectations stack up against these very different views.
